Replimune gains as FDA to discuss path for rejected skin cancer drug
Source: SeekingAlpha
2025-09-02 15:00:47 ET
More on Replimune Group
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Biotech sector slips amid reported return of ousted FDA official
- Biggest stock movers Monday: BLDE, COMM, SPOT, ON, and more
- Seeking Alpha’s Quant Rating on Replimune Group
Read the full article on Seeking Alpha
For further details see:
Replimune gains as FDA to discuss path for rejected skin cancer drug
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-6.4% G/L:
$7.02 Last:
1,610,656 Volume:
$7.66 Open:
REPL Latest News
February 03, 2026 08:00:00 am
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
December 18, 2025 08:00:00 am
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
